EchoCath gains clearance for EchoFlow

October 13, 1999

Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s

Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s applications include assessing the condition of blood vessels during and after surgery, determining proper placement of bypass grafts, and monitoring blood flow for implantable devices such as pacemakers, according to the Princeton, NJ-based firm. EchoCath will initially market EchoFlow to vascular surgeons for measuring blood-flow velocities but is also seeking corporate alliances for applications outside vascular surgery.